Stock Analysis of Blueprint Medicines Corp (BPMC) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code BPMC
Close 104.96
Change -1.68 / 1.58 %
Volume 415572
Vol Change 4089.00 / 0.994 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bearish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of Blueprint Medicines Corp
PE (TTM)

-22.39

Very Poor
Price / Book

23.57

Very Poor
Price / Sales

22.87

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

6572.27 M

Enterprise Value

6790.93 M

ROA (TTM)

-26.11

Very Poor
ROE (TTM)

-105.27

Very Poor
Net Margin (TTM)

-102.15

Very Poor
Revenue

5.96 %

216204 K
Net Profit

0.503 %

-554714.00 K
Debt to Equity

2.22

Poor
Altman Z Score

0.328

Poor
Quick Ratio

3.66

Very Good
Cash Ratio

3.31

Very Good


Highs/Lows of Blueprint Medicines Corp
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week106.7 1.63 % 1.54 % 111.02103.2314-May-2417-May-24
Two Week107.19 2.08 % 3.42 % 111.02103.2314-May-2417-May-24
One Month88.38 18.76 % 5.60 % 111.0284.6214-May-2419-Apr-24
Three Month90.26 16.29 % 5.95 % 111.0280.4214-May-2422-Feb-24
Six Months63.66 64.88 % 17.48 % 111.0263.514-May-2420-Nov-23
One year54.46 92.73 % 27.52 % 111.0243.8914-May-2425-Oct-23
Two year58.47 79.51 % 29.70 % 111.0237.8214-May-2424-Feb-23
Five year81.3 29.10 % 85.46 % 111.0237.8214-May-2424-Feb-23


Technical View of Blueprint Medicines Corp
RSI

59.90

Neutral
MACD

4.16

Bullish
ADX

24.28

Neutral
Super Trend

95.04

Mild Bullish
Williams %R

-29.89

Neutral
CCI

36.69

Bearish


EMA 5

106.09

Bearish
EMA 15

103.67

Bullish
EMA 50

96.02

Bullish
EMA 100

89.17

Strong Bullish
SMA 100

89.73

Strong Bullish
SMA 200

73.72

Strong Bullish
SMA 5 / 20

106.38 / 101.14

Bullish
SMA 15 / 50

104.27 / 94.45

Strong Bullish
SMA 50 / 200

94.45 / 73.72

Strong Bullish




Charts of Blueprint Medicines Corp


Returns of Blueprint Medicines Corp with Peers
Period / StockBPMCENSGMASIRVMD
1 Week-1.63%1.23%1.92%5.80%
1 Mth18.76%1.67%-9.16%7.03%
3 Mth16.29%-1.39%-7.86%33.55%
6mth64.88%11.55%32.32%84.76%
1 Year92.73%31.22%-26.10%51.99%
2 Year79.51%46.91%-11.34%138.42%
5 Years29.10%128.17%-11.84%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Blueprint Medicines Corp with Peers
Ratio / StockBPMCENSGMASIRVMD
PE-22.3931.5584.69-6572.11
P/B23.574.755.052587.40
ROA-26.115.362.62-34.77
ROE-105.2715.085.96-39.37
Debt To Equity2.220.1550.6390.0040
Revenue216204 K
5.96 % 		3558.51 M
17.62 % 		2048.10 M
0.604 % 		11580.00 K
67.27 %
Net Income-554714.00 K
0.503 % 		248179 K
10.46 % 		81500.00 K
43.21 % 		-436367.00 K
75.46 %


Technicals of Blueprint Medicines Corp with Peers
Technical / StockBPMCENSGMASIRVMD-
ADX24.2817.1427.5431.02
CMF-0.00010.138-0.03430.0402
MFI60.9363.7143.6465.60
RSI59.9054.6442.7762.86
MACD Abv SignalTrueTrueFalseFalse
Price Above 50 MATrueFalseFalseTrue-
Price Above 200 MATrueTrueTrueTrue-


About : Blueprint Medicines Corp

Address : 45 Sidney Street, Cambridge, MA, United States, 02139
Tel : 617 374 7580
URL : https://www.blueprintmedicines.com
Code : BPMC, ISIN : US09627Y1091, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 30_Apr_2015
Employee Count : 645

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.


Note : All Data Generated at the End of Trading Hours (EOD Data)